Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver - 1 Apr 2025

Lindén Daniel, Tesz Gregory, Loomba Rohit

Abstract excerpt

Metabolic dysfunction-associated steatotic liver disease (MASLD) is caused by metabolic triggers and genetic predisposition. Among the genetic MASLD risk variants identified today, the common PNPLA3 148M variant exerts the largest effect size of MASLD heritability. The PNPLA3 148M protein is causatively linked to the development of liver steatosis, inflammation and fibrosis in experimental studies and is...

Topics

Join the communities discussing this publication.

Acyltransferases
Fatty Liver
PNPLA3 gene
Genetic Predisposition to Disease
Lipase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Liver Cirrhosis

Membrane Proteins

Phospholipases A2, Calcium-Independent

Source

Open in PubMed Open full text

Identifiers

PMID: 39605307
DOI: 10.1111/liv.16186
PMCID: PMC11907219

Genes

PNPLA3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.PMID 39605307Read ↗

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.Semantic proximity Read ↗

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Semantic proximity Read ↗

Global epidemiology and implications of PNPLA3 I148M variant in MASLD: a systematic review and meta-analysisSemantic proximity Read ↗

PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.Semantic proximity Read ↗

PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver DiseaseSemantic proximity Read ↗

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.Semantic proximity Read ↗

Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatmentSemantic proximity Read ↗

A PNPLA3-Deficient iPSC-Derived Hepatocyte Screen Identifies Pathways to Potentially Reduce Steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease.Semantic proximity Read ↗

PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.Semantic proximity Read ↗

Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.Semantic proximity Read ↗

Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical applicationSemantic proximity Read ↗

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.